Terms: = Liver cancer AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR AND Prognosis
39 results:
1. Early Onset Intrahepatic Cholangiocarcinoma: Clinical Characteristics, Oncological Outcomes, and Genomic/Transcriptomic Features.
Tsilimigras DI; Han X; Guglielmi A; Aldrighetti L; Weiss M; Bauer TW; Alexandrescu S; Poultsides GA; Maithel SK; Marques HP; Martel G; Pulitano C; Shen F; Chaucy F; Koerkamp BG; Endo I; Sasaki K; Aucejo F; Zhang XF; Zhu H; Pawlik TM
Ann Surg Oncol; 2024 May; 31(5):3087-3097. PubMed ID: 38347332
[TBL] [Abstract] [Full Text] [Related]
2. Establishment and Validation of Novel Prognostic Subtypes in Hepatocellular Carcinoma Based on Bile Acid Metabolism Gene Signatures Using Bulk and Single-Cell RNA-Seq Data.
Qu Y; Gong X; Zhao Z; Zhang Z; Zhang Q; Huang Y; Xie Q; Liu Y; Wei J; Du H
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255993
[TBL] [Abstract] [Full Text] [Related]
3. Pemigatinib: A Review in Advanced Cholangiocarcinoma.
Frampton JE
Target Oncol; 2024 Jan; 19(1):107-114. PubMed ID: 38206555
[TBL] [Abstract] [Full Text] [Related]
4. Molecular Profile of Intrahepatic Cholangiocarcinoma.
Andraus W; Tustumi F; de Meira Junior JD; Pinheiro RSN; Waisberg DR; Lopes LD; Arantes RM; Rocha Santos V; de Martino RB; Carneiro D'Albuquerque LA
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203635
[TBL] [Abstract] [Full Text] [Related]
5. Comprehensive Analysis of the Sorafenib-Associated Druggable Targets on Differential Gene Expression and ceRNA Network in Hepatocellular Carcinoma.
Fu Z; Yang G; Wang T; Gao D; Lin D; Liu X
J Environ Pathol Toxicol Oncol; 2023; 42(4):47-60. PubMed ID: 37522567
[TBL] [Abstract] [Full Text] [Related]
6. Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma.
Zhang Z; Wang G; Du L; Zhao J; Pan L; Zhang G; Wang F; Liu R
Front Immunol; 2023; 14():1124482. PubMed ID: 37292215
[TBL] [Abstract] [Full Text] [Related]
7. Elevated nuclear PIGL disrupts the cMyc/BRD4 axis and improves PD-1 blockade therapy by dampening tumor immune evasion.
Yu H; Shi T; Yao L; Xu D; Ding Y; Xia Q; Liu W; Wang X
Cell Mol Immunol; 2023 Aug; 20(8):867-880. PubMed ID: 37280393
[TBL] [Abstract] [Full Text] [Related]
8. Precision oncology for intrahepatic cholangiocarcinoma in clinical practice.
Tomczak A; Springfeld C; Dill MT; Chang DH; Kazdal D; Wagner U; Mehrabi A; Brockschmidt A; Luedde T; Naumann P; Stenzinger A; Schirmacher P; Longerich T
Br J Cancer; 2022 Nov; 127(9):1701-1708. PubMed ID: 35986087
[TBL] [Abstract] [Full Text] [Related]
9. Genomic architecture of fgfr2 fusions in cholangiocarcinoma and its implication for molecular testing.
Neumann O; Burn TC; Allgäuer M; Ball M; Kirchner M; Albrecht T; Volckmar AL; Beck S; Endris V; Goldschmid H; Lehmann U; Seker-Cin H; Uhrig S; Roessler S; Budczies J; Fröhling S; Longerich T; Wagner AH; Vogel A; Schirmacher P; Stenzinger A; Kazdal D
Br J Cancer; 2022 Nov; 127(8):1540-1549. PubMed ID: 35871236
[TBL] [Abstract] [Full Text] [Related]
10. [Current Studies and Evidence in Cholangiocarcinoma].
Zimpel C; Mitzlaff K; Jasper NA; Marquardt JU
Zentralbl Chir; 2022 Aug; 147(4):389-397. PubMed ID: 35863357
[TBL] [Abstract] [Full Text] [Related]
11. Infigratinib for cholangiocarcinoma.
Sadeghi S
Drugs Today (Barc); 2022 Jul; 58(7):327-334. PubMed ID: 35851868
[TBL] [Abstract] [Full Text] [Related]
12. Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma.
Rimini M; Macarulla T; Burgio V; Lonardi S; Niger M; Scartozzi M; Rapposelli IG; Aprile G; Ratti F; Pedica F; Verdaguer H; Nappo F; Nichetti F; Lai E; Valgiusti M; Cappetta A; Febregat C; Fassan M; De Braud F; Puzzoni M; Frassineti GL; Simionato F; De Cobelli F; Aldrighetti L; Fornaro L; Cascinu S; Casadei-Gardini A
Eur J Cancer; 2022 Aug; 171():232-241. PubMed ID: 35749808
[TBL] [Abstract] [Full Text] [Related]
13. Proteogenomic characterization of cholangiocarcinoma.
Deng M; Ran P; Chen L; Wang Y; Yu Z; Cai K; Feng J; Qin Z; Yin Y; Tan S; Liu Y; Xu C; Shi G; Ji Y; Zhao JY; Zhou J; Fan J; Hou Y; Ding C
Hepatology; 2023 Feb; 77(2):411-429. PubMed ID: 35716043
[TBL] [Abstract] [Full Text] [Related]
14. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
Martin-Serrano MA; Kepecs B; Torres-Martin M; Bramel ER; Haber PK; Merritt E; Rialdi A; Param NJ; Maeda M; Lindblad KE; Carter JK; Barcena-Varela M; Mazzaferro V; Schwartz M; Affo S; Schwabe RF; Villanueva A; Guccione E; Friedman SL; Lujambio A; Tocheva A; Llovet JM; Thung SN; Tsankov AM; Sia D
Gut; 2023 Apr; 72(4):736-748. PubMed ID: 35584893
[TBL] [Abstract] [Full Text] [Related]
15. Unmet needs in the treatment of intrahepatic cholangiocarcinoma harboring
Beri N
Future Oncol; 2022 Apr; 18(11):1391-1402. PubMed ID: 35081733
[TBL] [Abstract] [Full Text] [Related]
16. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.
Dong L; Lu D; Chen R; Lin Y; Zhu H; Zhang Z; Cai S; Cui P; Song G; Rao D; Yi X; Wu Y; Song N; Liu F; Zou Y; Zhang S; Zhang X; Wang X; Qiu S; Zhou J; Wang S; Zhang X; Shi Y; Figeys D; Ding L; Wang P; Zhang B; Rodriguez H; Gao Q; Gao D; Zhou H; Fan J
Cancer Cell; 2022 Jan; 40(1):70-87.e15. PubMed ID: 34971568
[TBL] [Abstract] [Full Text] [Related]
17. Clinicopathological characteristics and survival outcomes in patients with synchronous lung metastases upon initial metastatic breast cancer diagnosis in Han population.
Lin S; Mo H; Li Y; Guan X; Chen Y; Wang Z; Xu B
BMC Cancer; 2021 Dec; 21(1):1330. PubMed ID: 34906122
[TBL] [Abstract] [Full Text] [Related]
18. Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma.
Tai DWM; Le TBU; Prawira A; Ho RZW; Huynh H
Hepatol Int; 2021 Oct; 15(5):1236-1246. PubMed ID: 34333737
[TBL] [Abstract] [Full Text] [Related]
19. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
Boerner T; Drill E; Pak LM; Nguyen B; Sigel CS; Doussot A; Shin P; Goldman DA; Gonen M; Allen PJ; Balachandran VP; Cercek A; Harding J; Solit DB; Schultz N; Kundra R; Walch H; D'Angelica MI; DeMatteo RP; Drebin J; Kemeny NE; Kingham TP; Simpson AL; Hechtman JF; Vakiani E; Lowery MA; Ijzermans JNM; Buettner S; Koerkamp BG; Doukas M; Chandwani R; Jarnagin WR
Hepatology; 2021 Sep; 74(3):1429-1444. PubMed ID: 33765338
[TBL] [Abstract] [Full Text] [Related]
20. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives.
Rizzo A; Ricci AD; Brandi G
Expert Opin Investig Drugs; 2021 Apr; 30(4):317-324. PubMed ID: 33054456
[TBL] [Abstract] [Full Text] [Related]
[Next]
